Study before-surgery treatments for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 3 trial compares different “treatments before surgery” for people with esophageal (or esophagus-to-stomach) cancer. It aims to see which approach works better to control the cancer and improve outcomes after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older
- Have esophageal or esophagogastric cancer confirmed by biopsy (either squamous cell or adenocarcinoma)
- Your cancer stage must be I to IVa (not beyond the nearby area)
- You should be scheduled to get your initial (primary) cancer treatment at the Cancer Hospital, Chinese Academy of Medical Sciences
- Your overall health must be good enough for treatment (ECOG 0–1) and you’re expected to live at least 3 months
- You must have blood tests and organ tests in safe ranges (including adequate blood counts, kidney function, and liver/clotting results)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests a cancer treatment plan that combines chemotherapy and radiation for people with esophageal or esophagus-stomach junction cancer. It aims to see whether this approach works better than standard care for cancers at stages I to IVA.
This trial studies whether adding radiation to chemotherapy before surgery works better for people with operable (resectable) squamous cell esophageal cancer. It aims to improve outcomes by comparing two different treatment plans before the operation.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests different combinations of treatments given before surgery for a type of esophageal cancer called squamous cell carcinoma. It aims to find the best approach to shrink the tumor and improve outcomes for patients whose cancer has not spread to distant organs.
This Phase 3 study compares two treatment plans before surgery for locally advanced esophageal squamous cell carcinoma. It tests whether adding pembrolizumab (an immune therapy) to chemotherapy improves outcomes compared with standard chemoradiation.
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (serplulimab and nimotuzumab) given before surgery for a certain type of esophageal cancer. It aims to see if this approach can safely improve outcomes.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.